Explore

Trendline Trendline
Biogen Advances Alzheimer's Drug Despite Phase 2 Trial Setback

Biogen Advances Alzheimer's Drug Despite Phase 2 Trial Setback

Biogen Advances Alzheimer's Drug Despite Phase 2 Trial Setback
Trendline Trendline
Biogen Advances Tau Alzheimer's Therapy to Phase 3 Amid Cautious Optimism

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Amid Cautious Optimism

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Amid Cautious Optimism
Trendline Trendline
Biogen Advances Alzheimer's Drug Diranersen to Phase 3 Despite Phase 2 Challenges

Biogen Advances Alzheimer's Drug Diranersen to Phase 3 Despite Phase 2 Challenges

Biogen Advances Alzheimer's Drug Diranersen to Phase 3 Despite Phase 2 Challenges
Trendline Trendline
Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback

Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback

Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback
Trendline Trendline
Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback
Trendline Trendline
Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges

Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges

Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges
Trendline Trendline
Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies for Neurodegenerative Diseases

Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies for Neurodegenerative Diseases

Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies for Neurodegenerative Diseases
Trendline Trendline
Biogen's Alzheimer's Drug Diranersen Moves to Phase 3 Despite Phase 2 Setbacks

Biogen's Alzheimer's Drug Diranersen Moves to Phase 3 Despite Phase 2 Setbacks

Biogen's Alzheimer's Drug Diranersen Moves to Phase 3 Despite Phase 2 Setbacks
Trendline Trendline
Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases

Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases

Kariya Pharmaceuticals and NeuraLight Collaborate on Brain-Focused GLP-1 Therapeutics for Neurodegenerative Diseases
Trendline Trendline
Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies

Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies

Kariya and NeuraLight Collaborate on Brain-Focused GLP-1 Therapies
Trendline Trendline
Fosun Pharma and AriBio Partner for Alzheimer's Drug Development

Fosun Pharma and AriBio Partner for Alzheimer's Drug Development

Fosun Pharma and AriBio Partner for Alzheimer's Drug Development
Trendline Trendline
Tiziana Life Sciences Reports Reduced Brain Inflammation in MSA Patients with Intranasal Foralumab

Tiziana Life Sciences Reports Reduced Brain Inflammation in MSA Patients with Intranasal Foralumab

Tiziana Life Sciences Reports Reduced Brain Inflammation in MSA Patients with Intranasal Foralumab